PHC-102 is a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors.

The product consists of a CAIX ligand derived from acetazolamide, a linker and a peptide 99mTC chelator.

CAIX is a validated target, which is expressed in the majority of Renal Cell Carcinoma (RCC) patients, but also in a proportion of patients with other malignancies (e.g., ~30% of patients with Colorectal Carcinoma).

In preclinical studies, PHC-102 demonstrated high tumor uptake and tumor-to-kidney ratios of up to 3.

This favorable selectivity may allow imaging of tumors in the kidney and distant sites at earlier time points than commonly possible with antibody-based products.

The product has recently entered Phase I clinical development in patients with RCC.


Krall (2016) J. Nucl. Med.; 57; 943-9
Krall (2014) Chem Sci (Camb).; 5; 3640–3644.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy